TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06653998

Intervention type: OTHER
Intervention: Early mobilization and rehabilitation
Description: In the initial assessment will be applied the ICU Mobility Scale, with the objective of establishing the patient\&#39;s current level of function and determining the most appropriate type, intensity and duration of activity.~The sessions, which will be conducted by a physiotherapist, will include therapeutic strategies such as bed exercises (both active and passive), electrical stimulation, use of an in-bed cycloergometer (for upper and lower limbs), sitting on the edge of the bed, bed transfers, bedside transfers from bed to chair, out-of-bed exercises, standing, and walking. The latter two activities are considered to be the most complex. Each session will last approximately 20 to 30 minutes and will be conducted once a day, on a daily basis throughout the patient\&#39;s ICU stay. The last session wil be prior to discharge of the patient.~During each session, the Borg Perception of Exertion Scale will be assessed in order to adjust the intensity of physical activity.
Study: NCT06654362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional interventions include education and modifying company's restaurant menu
Description: * Reducing fried foods and replacing them with healthier alternatives.~* Decreasing the consumption of sweetened beverages such as soda and replacing them with yogurt.~* Reducing the intake of refined grains and substituting with whole grains.~* Increasing fruit intake.~* Increasing the intake of vegetables as much as possible.~* Organizing face-to-face educational sessions with the chef to train them and improve cooking methods, to reduce fat and oil intake.
Study: NCT06654596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 240mg
Description: Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
Study: NCT06654128

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: artificial intelligence
Description: patients will undergo tandem colonoscopy with artificial intelligence
Study: NCT06604468

Intervention type: DIAGNOSTIC_TEST
Intervention: Thoracic bioimpedance tomography
Description: Data collection using a thoracic bioimpedance tomography device
Study: NCT06594458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Observation of newborn with respiratory distress in the delivery room
Description: Newborn manifesting tachypnea or respiratory distress at birth (that responds to supplementary oxygen with FiO2 \<30% and without the need for mechanical ventilation) are placed in a preheated incubator with the required oxygen concentration (if necessary) and carefully monitored by medical and nursing clinicians. A clinical evaluation will be carried out every 15 minutes, with the detection of vital parameters. In case of clinical improvement and suspension of oxygen therapy, the newborn will be transferred to the Neonatal Observation Ward to perform multiparameter monitoring of vital signs up to 6 hours of life and then be reunited with the mother. In case of clinical worsening, a bedside thoracic ultrasound will be carried out and depending on the result and the lung ultrasonography score, it will be evaluated whether to continue the observation in the delivery room or to admit the newborn in the Neonatal Care, Neonatal Sub-Intensive Care or Neonatal Intensive care Units
Study: NCT06597136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic kinesiology taping
Description: The taping on the diaphragm from the abdomen was performed when the participant was standing and breathed-out and the body was in extension. The base of the tape was about 1 inch below the xiphoid process area. Then the arms were lifted above the head and, with maximum deep inspiration and after maximum rib cage expansion, the tails were applied with 10% tension on the rib cage. Diaphragmatic kinesiology taping will be applied in addition to conventional treatment for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accessory respiratory muscle kinesiology taping
Description: Tapings of the accessory inspiratory muscles were applied in a sitting posture. Sternocleidomastoideus taping was applied when the neck of the participant was in lateral flexion to the opposite side to be taped and in rotation to the same side; and anterior and medius scalene tapings were applied when the neck of the participant was in the lateral flexion position to the opposite side to be taped. Tapings were repeated on the opposite side.Taping was applied to accessory expiratory muscles in the supine position. While the participant was supporting one leg in the hip and knee flexion position on the bed, the other leg was extended from the bed and the hip was kept in the extension position. The obliquus externus muscle was taped on the side with hip-knee flexion and the obliquus internus muscle was taped on the side with hip extension.In addition to conventional treatment, kinesiology taping will be applied to the accessory respiratory muscles for 3 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham kinesiology taping
Description: Sham kinesiology taping will be applied for 3 days. Sham KT was performed with the same taping material. A 2-blocked I strip was applied vertically to the sternum. The same procedures were followed.
Study: NCT06600984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: On a vibration platform, the children went into a complete squat. The device was calibrated at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 minutes. After the vibration was turned on, the children were told to stay in the squatting position and to report any discomfort that could occur. The vibration automatically shut off after five minutes. The children then rested for a minute. Next, under the identical conditions as for the squatting position, they were instructed to stand on the vibration platform for five minutes with the therapist\&#39;s assistance. Consequently, WBV was applied for a total of 10 minutes during each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physiotherapy program
Description: structured therapeutic exercise program that included neurodevelopmental approaches, balance exercises, milestone facilitation, stretching exercises, and postural reaction facilitation. The program was conducted for one hour each day, three days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physiotherapy program
Description: structured therapeutic exercise program that included neurodevelopmental approaches, balance exercises, milestone facilitation, stretching exercises, and postural reaction facilitation. The program was conducted for one hour each day, three days a week.
Study: NCT06598566

Intervention type: OTHER
Intervention: Nottingham Hip Fracture Score (NHFS) score
Description: Nottingham Hip Fracture Score (NHFS) score in patients above 60 years undergoing hip fracture surgery.

Intervention type: OTHER
Intervention: Acute Physiology and Chronic Health Evaluation (APACHE)-II score
Description: Acute Physiology and Chronic Health Evaluation (APACHE)-II score in patients above 60 years undergoing hip fracture surgery
Study: NCT06590103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physically Active Lessons
Description: Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the Physical Education teacher) are in charge of designing and delivering the physically active classes.
Study: NCT06594692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab
Description: Radiotherapy Protocol:~Short-course radiotherapy using three-dimensional conformal or intensity-modulated radiation therapy techniques. The radiation field will be limited to the tumor bed of the primary colon lesion, excluding surrounding draining lymph nodes and enlarged lymph nodes. The dose is fractionated as 5Gy per fraction, for a total of 25Gy over 5 fractions. Titanium clips will be placed on the proximal and distal ends of the colonic lesion via colonoscopy to guide radiation therapy positioning.~Chemotherapy Protocol (CAPOX Regimen):~1. Oxaliplatin: 130 mg/m², administered intravenously (ivgtt), on day 1 (d1).~2. Capecitabine: 1000 mg/m², orally (po), twice daily (bid), from day 1 to day 14 (d1-14).~Immunotherapy Protocol:~During preoperative treatment, Sintilimab (immune checkpoint inhibitor) will be administered concurrently with each chemotherapy cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX Chemotherapy
Description: Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
Study: NCT06591650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 800 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2, intravenous (IV) over 60 minutes, Days 1,8, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg, intravenous (IV) over 30 minutes, Days 1, every 21 days.
Study: NCT06586450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: The participants will receive Low Level Laser on lumbo-pelvic region for 20 min/sessions,3 sessions / week for 12 weeks, with the following parameters: Wavelength: 808 nm, continuous mode, Output power: 160 mw, Penetration depth: 4 cm, Power density:0.16 J/cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: All participants will receive interferential current on lumbopelvic region ( quadripolar technique) for 25 min/session, 3 sessions/week for 12 weeks, with the following parameters: carrier frequency of 4 KHZ and sweep frequency 95 HZ, intensity based on patient's tolerance without muscle contraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercise
Description: The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Description: The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Description: The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.
Study: NCT06655519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T（RD140 injection）
Description: This study is divided into two stages: dose escalation and dose extension. The dose escalation stage sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 1.0×10\^5 CART cells/kg, 3.0×10\^5 CART cells/kg and 6.0×10\^5 CART cells/kg, and subjects will receive a single infusion of RD140. Each dose group level will include 3-6 subjects.~In the dose expansion stage, 1\~2 dose groups were selected for expansion and 3\~6 subjects were included in each extended dose group, and the target dose was administered once.
Study: NCT06225011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Receive PO
Study: NCT05601947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Proprioception and Closed Kinetic Chain Exercises Group
Description: In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Based Balance Training Program Group
Description: In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes.
Study: NCT06300385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyostimulation
Description: Electromyostimulation (EMS), a low-frequency current, will be used for electrical stimulation of the wrist flexor muscle group. Stimulation frequency will be applied as 25 Hertz. Care will be taken to ensure that the current intensity does not cause pain in the patient. The size of the EMS electrodes is 2 cm2 and they will be placed in the form of 4 electrodes on the wrist flexor muscles (inner wrist area) with a distance of 1 cm between them. Each strengthening session will be 15 minutes for 6 weeks, 3 days a week, for a total of 18 sessions. EMS application will be carried out together with strengthening exercises. Laica MD6078 branded device belonging to the researchers will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: All participants will do resistance exercises for strengthening, 3 sessions per week for 6 weeks. Each movement will be performed in 3 sets and 12 repetitions according to the planned intensity. Wrist curl, reverse wrist curl movements (with 10kg dumbbells) and power web flex grip movements will be applied simultaneously with EMS application. The program will last 15 minutes in total.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Strengthening exercises
Description: All participants will do resistance exercises for strengthening, 3 sessions per week for 6 weeks. Each movement will be performed in 3 sets and 12 repetitions according to the planned intensity. Wrist curl, reverse wrist curl movements (with 10kg dumbbells) and power web flex grip movements will be applied simultaneously with EMS application. The program will last 15 minutes in total.
Study: NCT05969743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
Study: NCT05714748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV mRNA vaccine
Description: With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
Study: NCT06267586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PeptiSleep
Description: Plant protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PeptiSleep
Description: Plant protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PeptiSleep
Description: Plant protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MCC micro-crystalline cellulose
Description: Placebo MCC micro-crystalline cellulose
Study: NCT05997368

Intervention type: OTHER
Intervention: Survey1
Description: As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing

Intervention type: OTHER
Intervention: Survey2
Description: As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing

Intervention type: OTHER
Intervention: Survey3
Description: As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
Study: NCT06389955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP 3654
Description: TP 3654 is an investigational orally delivered drug
Study: NCT06601595

Intervention type: DRUG
Intervention: TNF inhibitors
Description: tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease

Intervention type: DRUG
Intervention: conventional ibd medical treatment
Description: Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
Study: NCT06592638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study: NCT05074290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiferphane
Description: During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane Chemotherapy
Description: All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Study: NCT06603389

Intervention type: OTHER
Intervention: Psychiatric Non-Suicidal Self-Injury Risk Assessment Scale
Description: sacles or questionnaires
Study: NCT06597240

Intervention type: DEVICE
Intervention: AMCOR
Description: Participants will collect biometric and quality of life data for 11 weeks at home. Continuous step counting will be used to register physical activity. Participants will be asked to measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature each morning, and weight 3 times a week. These measurements consume little time and are not harmful. Once a week they will perform a finger stick test themselves to determine creatinine concentration in the blood. In addition, patients fill in three questionnaires at four time points which will take approximately 20 minutes to complete per time point. We do not foresee reasonable risks of these diagnostic procedures for the participants.
Study: NCT06604117

Intervention type: DRUG
Intervention: Statin
Description: Participants who opt for this group will receive guideline-recommended conventional lipid-lowering therapy. For those with a history of ischemic stroke (IS), myocardial infarction (MI), acute coronary syndrome within the past year, symptomatic peripheral artery disease, or two or more high-risk factors, the target LDL-C level will be set at 1.4 mmol/L. For other IS participants, the LDL-C target will be set at 1.8 mmol/L. All participants will receive moderate-intensity statin therapy as the primary treatment. If LDL-C levels are not adequately controlled, ezetimibe will be added. If lipid levels remain unsatisfactory, the addition of PCSK9 inhibitors will be considered. Moderate-intensity statins are defined as atorvastatin 10-20 mg or rosuvastatin 5-10 mg.

Intervention type: DRUG
Intervention: Probucol
Description: Participants who choose this group will receive Probucol in combination with guideline-recommended lipid-lowering therapy. Specifically, participants in this group will take 0.5 grams of Probucol twice daily alongside the conventional lipid-lowering therapy mentioned in Group 1. The combination of Probucol and conventional therapy aims to further improve lipid profile and address atherosclerosis.